Contra los productos ya conocidos, la novedad mostr reducir hasta un 26% el peso en 72 semanas de tratamiento, en comparacin con el inyectable que la precede (semaglutida), que lleg hasta el 17%, ambos frmacos en dosis mximas
Results Solid gastric content was similar between GLP-1 users (4/74, 5.4%) and controls (3/60, 5.0%) (p = 0.563)
Conclusion Tirzepatide produced significant health- and weight-related QoL improvements versus comparators in the SURPASS-1 to -5 studies along with substantial improvements in glycaemic control and body weight
Patients can expect minimal downtime and manageable side effects, with many experiencing significant weight loss and improved overall health
However, indirect interactions can still happen
Storing ZEPBOUND Do not freeze